Training Transformers to Address the 95% Failure Rate in Cancer Trials — Noetik
Noetik uses TARIO-2 to predict tumor spatial transcriptomics, targeting a 95% cancer-trial failure rate. GSK signed a $50M technology deal, and TARIO-2 predicts a ~19,000-gene spatial map from routine H&E assays. The key issue is patient-tumor-treatment matching, not the claim that AI cures cancer.
Why it matters: Noetik trained an autoregressive Transformer to predict spatial expression of about 19,000 genes from routine H&E slides, tracing cancer trials' high failure rate to patient, tumor and drug pairing.